These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 10874665

  • 21. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas.
    Schneider-Stock R, Walter H, Radig K, Rys J, Bosse A, Kuhnen C, Hoang-Vu C, Roessner A.
    J Cancer Res Clin Oncol; 1998; 124(10):532-40. PubMed ID: 9829856
    [Abstract] [Full Text] [Related]

  • 22. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status.
    McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G, Dervan PA.
    Br J Cancer; 1995 May; 71(5):981-5. PubMed ID: 7734324
    [Abstract] [Full Text] [Related]

  • 23. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
    Gorgoulis VG, Rassidakis GZ, Karameris AM, Papastamatiou H, Trigidou R, Veslemes M, Rassidakis AN, Kittas C.
    Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
    [Abstract] [Full Text] [Related]

  • 24. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
    Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H.
    J Clin Oncol; 2006 Sep 20; 24(27):4434-40. PubMed ID: 16983111
    [Abstract] [Full Text] [Related]

  • 25. Molecular analysis for p53 and mdm2 in intracranial germ cell tumors.
    Iwato M, Tachibana O, Tohma Y, Nitta H, Hayashi Y, Yamashita J.
    Acta Neuropathol; 2000 Jan 20; 99(1):21-5. PubMed ID: 10651023
    [Abstract] [Full Text] [Related]

  • 26. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.
    Miyajima K, Tamiya S, Oda Y, Adachi T, Konomoto T, Toyoshiba H, Masuda K, Tsuneyoshi M.
    Cancer Lett; 2001 Mar 26; 164(2):177-88. PubMed ID: 11179833
    [Abstract] [Full Text] [Related]

  • 27. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
    Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, Houghton PJ, Harris LC.
    Med Pediatr Oncol; 2000 Aug 26; 35(2):96-103. PubMed ID: 10918230
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
    Wojcik I, Szybka M, Golanska E, Rieske P, Blonski JZ, Robak T, Bartkowiak J.
    Neoplasma; 2005 Aug 26; 52(4):318-24. PubMed ID: 16059649
    [Abstract] [Full Text] [Related]

  • 30. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
    Osman I, Scher HI, Zhang ZF, Pellicer I, Hamza R, Eissa S, Khaled H, Cordon-Cardo C.
    Clin Cancer Res; 1997 Apr 26; 3(4):531-6. PubMed ID: 9815716
    [Abstract] [Full Text] [Related]

  • 31. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
    Suda T, Yoshihara M, Nakamura Y, Sekiguchi H, Godai TI, Sugano N, Tsuchida K, Shiozawa M, Sakuma Y, Tsuchiya E, Kameda Y, Akaike M, Matsukuma S, Miyagi Y.
    Oncol Rep; 2011 Jul 26; 26(1):49-54. PubMed ID: 21503588
    [Abstract] [Full Text] [Related]

  • 32. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
    Wang YC, Lin RK, Tan YH, Chen JT, Chen CY, Wang YC.
    J Clin Oncol; 2005 Jan 01; 23(1):154-64. PubMed ID: 15625370
    [Abstract] [Full Text] [Related]

  • 33. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature.
    Boltze C, Schneider-Stock R, Jäger V, Roessner A.
    Pathol Res Pract; 2001 Jan 01; 197(8):563-8. PubMed ID: 11518050
    [Abstract] [Full Text] [Related]

  • 34. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
    Molina P, Pellín A, Navarro S, Boix J, Carda C, Llombart-Bosch A.
    Virchows Arch; 1999 Dec 01; 435(6):596-605. PubMed ID: 10628802
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia.
    Tanière P, Martel-Planche G, Maurici D, Lombard-Bohas C, Scoazec JY, Montesano R, Berger F, Hainaut P.
    Am J Pathol; 2001 Jan 01; 158(1):33-40. PubMed ID: 11141476
    [Abstract] [Full Text] [Related]

  • 37. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.
    Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S, Theillet C.
    Cancer Res; 2000 Feb 15; 60(4):1077-83. PubMed ID: 10706127
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.